Moody's views Regeneron positively

Moody's Investors Service said it affirmed the Baa3 senior unsecured ratings of Regeneron Pharmaceuticals, Inc. and revised the outlook to positive from stable.

“The outlook revision to positive reflects Moody's anticipation for strong growth in Dupixent and Libtayo, helping to improve revenue diversity and ease concerns about upcoming biosimilar competition for Eylea (aflibercept). At the same time, Phase III studies of a higher-dose version of aflibercept are underway with data anticipated later this year, potentially easing these concerns further,” the agency said in a press release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.